In CHO-AT1 cells, candesartan inhibited surface [3H]-angiotensin II binding with an IC50 of 0.26 ± 0.05 nM without BSA and 0.69 ± 0.14 nM with 0.1% BSA. Potency depended on assay conditions. [1]
In PC3 cells, 24-hour treatment at 0.5, 5 and 25 µM did not significantly suppress proliferation or viability and reduced apoptosis-associated DNA fragmentation. The mouse tumor result therefore should not be interpreted as evidence of direct PC3 cell killing. [2]
In GIST-T1 cells, 100 µM candesartan reduced the CCK-8 viable-cell signal at 48 hours. The accompanying cell-cycle experiments tested telmisartan, so they do not establish a candesartan-specific mechanism. [3]
AT1 binding and functional antagonism in CHO cells
Cell-based study · CHO-K1 cells stably expressing human AT1 receptors (CHO-AT1) [1]
Candesartan inhibited surface radioligand binding and AngII-induced IP accumulation. Pretreatment suppressed maximal agonist responses, unlike losartan. Wild-type CHO-K1 cells lacked specific binding/AngII responses.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response experiments; Figure 3a: 0.5, 1.5 and 5 nM
- Exposure duration
- 30 min antagonist preincubation; 30 min radioligand binding or 5 min AngII functional challenge
- Method
- Intact-cell [3H]-AngII binding with acid-releasable surface fraction; radiolabeled inositol-phosphate accumulation at 37°C
- Vehicle
- DMEM; Table 1 compares absence/presence of 0.1% BSA
- Reported limits
- Antagonist stock solvent not specified in read Drugs used section.
Methods and source locations
Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974
Reported experimental material; no prodrug dose conversion or lot equivalence.
Table 1 and Figure 3a,d; Methods: Drugs used, IP accumulation and [3H]-Angiotensin II binding; Results: antagonist effects
Surface binding of 1 nM [3H]-AngII without BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)
Surface binding of 1 nM [3H]-AngII with 0.1% BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)
IP accumulation induced by 0.1 µM AngII without BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)
IP accumulation induced by 0.1 µM AngII with 0.1% BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)
Recovery of AT1 signaling after antagonist washout
Cell-based study · CHO-AT1 cells [1]
AngII responses recovered slowly after candesartan removal. Persistent inhibition alone does not prove continued receptor occupancy; the authors retain conformational and rebinding alternatives.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 or 5 nM candesartan; losartan comparator 300 or 1000 nM
- Exposure duration
- 30 min pretreatment; washout/fresh-medium recovery for up to 5 h; 0.1 µM AngII challenge for 5 min
- Method
- IP accumulation after antagonist washout, normalized to time-matched medium-only controls
- Vehicle
- DMEM
- Reported limits
- Antagonist stock solvent not specified.
Methods and source locations
Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974
Reported experimental material; no prodrug dose conversion or lot equivalence.
Figure 5a,d and associated Results; Methods: IP accumulation/recovery experiments
Residual suppression of AngII-induced IP accumulation after 4 h recovery: Results numerical values; Figure 5 legend: average ± s.e.mean, at least three independent determinations, performed in triplicate. — Figure 5a and Results: washout experiments
PC3 cellular responses include limited antiproliferative activity
Cell-based study · Human PC3 prostate cancer cells [2]
At the concordantly documented 0.5, 5 and 25 µM concentrations, candesartan did not significantly suppress BrdU proliferation or MTT viability and reduced apoptosis-associated DNA fragmentation. These results limit interpretation of tumor-growth inhibition as direct tumor-cell killing.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5, 5 and 25 µM (concordant methods/figure levels); full figure also includes 50 and 200 µM
- Exposure duration
- 24 h
- Method
- BrdU incorporation, MTT conversion and histone-associated DNA-fragment ELISA under serum-free conditions
- Vehicle
- Serum-free DMEM; control DMEM alone
- Reported limits
- Methods list 10 µM where parts of Figure 2 show 50 µM; do not reconcile these as equivalent. Stock solvent and matched vehicle for these assays not clearly specified; another assay mentions DMSO.
Methods and source locations
Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974
Reported experimental material; no prodrug dose conversion or lot equivalence.
Figure 2A–D; associated Results; Methods: proliferation, viability, apoptosis and migration assays
Apoptosis-associated DNA fragments; BrdU incorporation; MTT viability: Figure 2 shows n = 4 and mean ± S.D.; no exact bar heights inferred. — Figure 2A,C,D and corresponding Results
Candesartan comparison in GIST-T1 cells
Cell-based study · Human GIST-T1 cells [3]
Candesartan at 100 µM reduced the CCK-8 viable-cell signal relative to 0 µM control at 48 h. The cell-cycle and signaling experiments used telmisartan and cannot establish the mechanism of this candesartan result.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 1, 10 and 100 µM
- Exposure duration
- 48 h treatment in methods; Figure 1 additionally plots 24 h
- Method
- CCK-8 assay; absorbance at 450 nm, in DMEM with 10% FBS
- Vehicle
- DMSO stock; methods include 0 µM/vehicle control
- Reported limits
- Final matched DMSO percentage not specified. CCK-8 is a viable-cell metabolic readout, not direct cell counting. Biological versus technical triplicate distinction is not specified in statistical methods.
Methods and source locations
Compound reported in the paper: Candesartan; Compound label in the paper: candesartan
Reported experimental material; no prodrug dose conversion or lot equivalence.
Figure 1 candesartan panel; Methods: Chemicals and antibodies, Cell culture, Cell proliferation assay, Statistical analyses; first Results subsection
CCK-8 viable-cell signal at 48 h versus 0 µM: Triplicate in-vitro experiments; results mean ± SD. No precise curve values or IC50 inferred. — Figure 1 candesartan panel; Statistical analyses